Program Highlights

The aim of the session is to provide clinicians with a practical and clinically relevant overview of how emerging molecular and computational methods may impact cervical screening and triage in the coming years, while also discussing important limitations in interpretation and implementation.

As the majority of the world has now adopted single dose HPV vaccination for adolescent girls, this session seeks to consider data for expanded use of single-dose HPV vaccination that will accelerate progress towards control of not just cervical cancer, but all HPV-driven cancers. The session will begin with the state of the science around single-dose HPV vaccination as well as a presentation in the gaps in knowledge. Then, the status of research studies, as well as results when available, will be presented on the following critical topics when considering expanded use for single-dose HPV vaccination: adult women using cervical and anal HPV endpoints, vulnerable women who acquire HIV, toddlers and males. The session will conclude with a presentation on global modeling work that identified the potential for increased cervical cancer inequalities worldwide without enhanced prevention efforts, as well as impact of expanded single-dose HPV vaccination of prevention of non-cervical HPV-driven cancers.

Solid organ transplant recipients experience substantially elevated rates of persistent HPV infection and HPV-associated malignancies. Chronic immunosuppression to prevent graft rejection alters viral clearance, immune surveillance, and tumor progression. As transplant survival improves and global transplantation rates increase, prevention of HPV-associated cancers in SOT recipients represents an urgent and under-addressed public health priority.

-